Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML
对于FLT3-ITD突变型急性髓系白血病患者,可测量的残留病灶和移植后吉瑞替尼维持治疗。
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2024025154
Levis, Mark J; Hamadani, Mehdi; Logan, Brent R; Jones, Richard J; Singh, Anurag K; Litzow, Mark R; Wingard, John R; Papadopoulos, Esperanza B; Perl, Alexander E; Soiffer, Robert J; Ustun, Celalettin; Oshima, Masumi Ueda; Uy, Geoffrey L; Waller, Edmund K; Vasu, Sumithira; Solh, Melhem; Mishra, Asmita; Muffly, Lori S; Kim, Hee-Je; Stelljes, Matthias; Najima, Yuho; Onozawa, Masahiro; Thomson, Kirsty; Nagler, Arnon; Wei, Andrew H; Marcucci, Guido; Chen, Caroline; Hasabou, Nahla; Rosales, Matt; Hill, Jason; Gill, Stanley C; Nuthethi, Rishita; King, Denise; Mendizabal, Adam; Devine, Steven M; Horowitz, Mary M; Chen, Yi-Bin